These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 18178097

  • 1. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
    Cibeira MT, Rozman M, Segarra M, Lozano E, Rosiñol L, Cid MC, Filella X, Bladé J.
    Cytokine; 2008 Mar; 41(3):244-53. PubMed ID: 18178097
    [Abstract] [Full Text] [Related]

  • 2. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
    Hatjiharissi E, Terpos E, Papaioannou M, Hatjileontis C, Kaloutsi V, Galaktidou G, Gerotziafas G, Christakis J, Zervas K.
    Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
    [Abstract] [Full Text] [Related]

  • 3. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
    Du W, Hattori Y, Hashiguchi A, Kondoh K, Hozumi N, Ikeda Y, Sakamoto M, Hata J, Yamada T.
    Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
    [Abstract] [Full Text] [Related]

  • 4. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival.
    Andersen NF, Standal T, Nielsen JL, Heickendorff L, Borset M, Sørensen FB, Abildgaard N.
    Br J Haematol; 2005 Jan; 128(2):210-7. PubMed ID: 15638855
    [Abstract] [Full Text] [Related]

  • 5. Angiogenesis in multiple myeloma.
    Jakob C, Sterz J, Zavrski I, Heider U, Kleeberg L, Fleissner C, Kaiser M, Sezer O.
    Eur J Cancer; 2006 Jul; 42(11):1581-90. PubMed ID: 16797965
    [Abstract] [Full Text] [Related]

  • 6. Circulating angiogenic cytokines in multiple myeloma and related disorders.
    Urba ska-Rys H, Wierzbowska A, Robak T.
    Eur Cytokine Netw; 2003 Jul; 14(1):40-51. PubMed ID: 12799213
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
    Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Russell SJ, Greipp PR.
    Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422
    [Abstract] [Full Text] [Related]

  • 11. Response to thalidomide in multiple myeloma: impact of angiogenic factors.
    Rosiñol L, Cibeira MT, Segarra M, Cid MC, Filella X, Aymerich M, Rozman M, Arenillas L, Esteve J, Bladé J, Montserrat E.
    Cytokine; 2004 May 21; 26(4):145-8. PubMed ID: 15149630
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Bone marrow microvascular density and angiogenic growth factors in multiple myeloma.
    Alexandrakis MG, Passam FJ, Ganotakis E, Dafnis E, Dambaki C, Konsolas J, Kyriakou DS, Stathopoulos E.
    Clin Chem Lab Med; 2004 May 21; 42(10):1122-6. PubMed ID: 15552270
    [Abstract] [Full Text] [Related]

  • 15. New drugs for myeloma.
    Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K.
    Oncologist; 2007 Jun 21; 12(6):664-89. PubMed ID: 17602058
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma].
    Li J, Luo SK, Hong WD, Zhou ZH, Zou WY.
    Ai Zheng; 2003 Apr 21; 22(4):346-9. PubMed ID: 12703985
    [Abstract] [Full Text] [Related]

  • 19. Bone marrow angiogenesis in multiple myeloma and its correlation with clinicopathological factors.
    Rana C, Sharma S, Agrawal V, Singh U.
    Ann Hematol; 2010 Aug 21; 89(8):789-94. PubMed ID: 20177896
    [Abstract] [Full Text] [Related]

  • 20. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.
    Mileshkin L, Honemann D, Gambell P, Trivett M, Hayakawa Y, Smyth M, Beshay V, Ritchie D, Simmons P, Milner AD, Zeldis JB, Prince HM.
    Haematologica; 2007 Aug 21; 92(8):1075-82. PubMed ID: 17640854
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.